Merck’s Keytruda®: update on trials and outcomes
EPR’s Anna Begley summarises some of the key results from trials of Merck’s Keytruda® (pembrolizumab) cancer treatment.
List view / Grid view
EPR’s Anna Begley summarises some of the key results from trials of Merck’s Keytruda® (pembrolizumab) cancer treatment.
EPR's Anna Begley reviews some of the latest results for AstraZeneca’s Enhertu (trastuzumab deruxtecan) HER2-directed cancer therapy.
In this article, European Pharmaceutical Review’s Hannah Balfour explores some of big pharma’s latest developments in HIV treatment, with commentary from ViiV Healthcare’s Head of Research and Development, Kimberly Smith.
3D printing has the potential to revolutionise the pharmaceutical manufacturing industry; however, few 3D-printed products have been approved since the first in 2015. In this article, EPR’s Hannah Balfour explores the technologies currently being evaluated for use in the 3D printing of pharmaceuticals, and the work of key market players…
In this article, Included’s Raafi-Karim Alidina explores biases in product design, outlining how they impact pharmaceuticals as well as technologies, and practical steps to enhance diversity and ensure inclusion.
In this article, EPR's Hannah Balfour outlines six factors that could significantly challenge the generics and biosimilars market in the next decade.
Antibody therapeutics revolutionised how diseases like cancer are treated in the developed world, but their high manufacturing cost and cumbersome distribution and administration leave them out of reach for most. In this guest article, Lumen Bioscience’s CEO, Brian Finrow, and EVP of Production & Development, Craig Behnke, discuss how new…
Optical spectral measurement tools are extremely useful both for in-line measurements in process analytical techniques (PATs) as well as for evaluating the composition of finished substances. Here, CPI’s Lukas Kuerten and Rachel Findlay demonstrate a valuable method for gaining useful information from spectral data.
Here, EPR explores some highlights of the UK’s new Life Sciences Vision for the pharma, biopharma and biotech industries, covering topics from funding to regulatory reviews and clinical trial innovation.
Here, Dave Elder discusses the ever increasing importance of child-friendly medications and the specific challenges associated with their development.
Nathalie Moll, Director General of the European Federation of Pharmaceutical Industries and Associations (EFPIA) gives her take on the industry response to the pandemic; highlighting the benefits of focused effort and what can be achieved through unified collaboration.
Infusion is the most used technology in hospitals. Given its widespread application, often in critical situations and by many users, infusion errors are frequently made, with some having severe effects. Here, Emmelyn Graham, Flow Measurement Engineer at TÜV SÜD National Engineering Laboratory, and Elsa Batista, Head of Volume and Flow…
It might be easy to dismiss non-life-threatening diseases of the skin or nail as trivial, but their impact on physical and mental wellbeing can be significant. Such diseases are obvious targets for topical treatments, but the lack of effective formulations means patients are often faced with the prospect of oral…
The COVID-19 pandemic spotlighted drug repurposing as a key strategy to support traditional novel chemical entity development; yet repurposing is just one example of how off-patent molecules can be further developed to provide patients with more treatment options. Here, Arun Narayan, Chairman of the Value Added Medicines Sector Group at…
Advanced therapies are a ground-breaking new class of medicines that use gene therapy, cell therapy or tissue engineering to treat disease and injury. Rachel Bell, Trainee Patent Attorney at Marks & Clerk, and Ceri Roberts, Scientific Training Manager – Cellular and Molecular Therapies at NHS Blood and Transplant, discuss some…